IPCALAB1,972.10

Ipca Laboratories Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersTORNTPHARMALKEMJBCHEPHARMABBOTINDIAAJANTPHARMANTHEMGLAXOMEDANTAMcap ₹50,032 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations7,705.08,939.69,646.310,125.6
Other Income124.892.8174.5167.1
Total Income7,829.89,032.49,820.810,292.6
Expenses
+ Cost of Materials Consumed2,216.32,276.82,344.02,365.1
+ Purchases of Stock-in-Trade490.1547.8532.6546.6
+ Changes in Inventories-130.6-46.1-53.916.9
+ Employee Benefit Expense1,708.41,984.02,160.22,218.6
+ Finance Costs138.384.975.969.3
+ Depreciation & Amortisation357.2397.8418.1428.9
+ Other Expenses2,099.72,450.92,684.92,746.8
Total Expenses6,879.47,696.28,161.88,392.1
EBITDA1,321.21,726.11,978.62,231.7
EBIT963.91,328.31,560.41,802.8
Profit
PBT before Exceptional Items950.41,336.21,659.01,900.5
+ Exceptional Items-107.8-205.1-86.4-86.4
Pretax Income842.71,131.11,572.51,814.1
+ Current Tax310.2372.1417.8455.0
+ Deferred Tax3.3-28.4-36.7-20.6
Tax Expense313.5343.6381.2434.3
+ Share of Associates & JVs-6.3-2.3-7.6-4.6
Net Income522.9785.21,183.81,375.2
+ Net Income — Continuing Ops529.2787.51,191.41,379.8
+ Other Comprehensive Income-9.5-24.642.817.7
Total Comprehensive Income513.5760.71,226.51,392.9
Net Income to Common547.4737.71,141.11,309.8
Minority Interest-24.447.642.765.4
Per Share
Basic EPS21.5729.0844.9851.63
Diluted EPS21.5729.0844.9851.63
Other Comprehensive Income — detail
+ Other Comprehensive Income-24.642.817.7
+ Items NOT to be Reclassified to P&L-8.8-5.116.1-4.3
+ Tax on Items NOT to be Reclassified-1.93.8-0.0
+ Tax on Items NOT to be Reclassified — alt tag-0.6
+ Items to be Reclassified to P&L-1.3-22.130.922.6
+ Tax on Items to be Reclassified-0.70.50.6
+ Tax on Items to be Reclassified — alt tag-0.0
Comprehensive Income — Owners of Parent539.3716.71,178.21,324.8
Comprehensive Income — Non-controlling Interests-25.844.048.368.1
Per Share — as-filed variants
Basic EPS — Continuing Operations21.5729.0844.9851.63
Diluted EPS — Continuing Operations21.5729.0844.9851.63
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit5,129.36,161.06,823.67,197.1
Gross Margin %66.5768.9270.7471.08
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)950.41,336.21,659.01,900.5
− Exceptional Items (reconciliation)-107.8-205.1-86.4-86.4
Net Income Adj (tax-effected)590.6928.01,249.31,440.9
EPS Adj24.3634.3747.4754.10
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital25.425.425.425.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.